Mon, Mar 17, 9:24 PM (41 days ago)
**PharmaCyte Biotech, Inc. (PMCB) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** No revenue reported for Q1 and Q3 2025. - **Operating Expenses:** Q1 2025 saw a decrease of $908,694 in operating expenses compared to Q1 2024, primarily due to reductions in R&D costs, compensation, director fees, and general administrative expenses. - **Net Income/Loss:** Q1 2025 reported a net loss of $3.05 million, compared to a net loss of $0.62 million in Q1 2024. For the nine months ended January 31, 2025, the company reported a net income of $18.91 million, primarily due to gains on investments. - **Cash Flow:** Net cash used in operating activities was $1.94 million for Q3 2025, compared to $1.82 million in Q3 2024. Significant cash outflows were noted in investing and financing activities, totaling $33.80 million and $24.86 million, respectively, for Q3 2025. - **Cash Position:** Cash and cash equivalents decreased to $16.4 million as of January 31, 2025, from $50.2 million as of April 30, 2024, due to increased redemptions of preferred stock, common stock repurchases, and investments. **Key Metrics and Trends:** - **Profit Margins:** The company reported a net loss margin of 100% for Q1 2025, indicating ongoing financial challenges. - **Earnings Changes:** The significant gain in net income for the nine months ended January 31, 2025, was driven by a $21.40 million gain on a related party investment. - **Investments:** The company made strategic investments in TNF Pharmaceuticals, Inc. and Femasys Inc., with notable changes in the fair value of these investments impacting earnings. **Future Operations and Uncertainties:** - **Liquidity:** The company expects its current cash position to support operating requirements for at least the next 12 months but may need additional capital for future projects. - **Regulatory Challenges:** The FDA's clinical hold on the company's IND for LAPC treatment remains a significant hurdle, with ongoing studies and submissions required to lift the hold. - **Operational Impact:** The company has curtailed spending on development programs pending a review by the Business Review Committee and the Board, which may impact future operational timelines and outcomes. **Conclusion:** PharmaCyte Biotech, Inc. faces significant financial and regulatory challenges, with a focus on managing cash flow, addressing the FDA's clinical hold, and strategically investing in future growth opportunities. The company's ability to secure additional funding and successfully navigate regulatory hurdles will be critical to its long-term success.